GlassScriptPhysician profile
Edward I Nelson
NPI 1720085459
$3,305.29
in general payments reported to CMS, 2019-2025
26 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $141 · 2021: $820 · 2022: $539 · 2023: $428 · 2024: $561 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.35 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $622.31 | 2021-2025 | Belbuca, Xtampza |
| Amgen INC. | $402.94 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $196.01 | 2021 | |
| Pfizer INC. | $192.97 | 2019-2025 | |
| Biodelivery Sciences International, INC. | $169.16 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.57 | 2022 | |
| Indivior INC. | $96.35 | 2019-2025 | Sublocade |
| Tersera Therapeutics LLC | $84.24 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $80.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.40 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $57.93 | 2019 | |
| Lilly USA, LLC | $54.29 | 2019-2022 | |
| Vertos Medical, INC. | $40.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.72 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $33.00 | 2022 | |
| Abbott Laboratories | $29.54 | 2021-2025 | Proclaim |
| Alkermes, INC. | $28.82 | 2023 | Vivitrol |
| Orexo US, INC. | $28.40 | 2020-2021 | |
| Tonix Medicines, INC. | $26.71 | 2025 | Tonmya |
| Averitas Pharma INC. | $19.81 | 2024 | Qutenza |
| Merz Pharmaceuticals, LLC | $19.44 | 2025 | Xeomin |
| Kaleo, INC. | $18.11 | 2019 | |
| Allergan, INC. | $14.99 | 2021 | |
| Daiichi Sankyo INC. | $14.90 | 2019 | |
| Grt US Holding, INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.